Medscape’s Post

Hope you can join us for this webcast! #obesitymedicine #obesity

NACE Webcast Alert: Practical Strategies for Obesity Management in Primary Care! In this webcast, recorded from NACE’s 2024 Emerging Challenges and Clinical Updates in Primary Care, in collaboration with the American Academy of Physician Associates and The Obesity Society, Drs. Angela Golden, DNP, FAANP, FOMA and Robert Kushner, MD and Karlijn Burridge, PA-C, MMS, FOMA discuss the pathophysiology of obesity and its effects on cardiovascular, renal, and metabolic disease. They highlight explicit and implicit biases associated with obesity and describe strategies to minimize bias toward individuals affected by obesity to optimize clinical encounters. Finally, they provide an overview of a multicomponent approach to obesity that includes lifestyle intervention, behavioral therapy, and pharmacologic treatment. This recording is being used with the permission of the presenters. Click here to start the course: https://bit.ly/4bNwIN4 #Webcast #NACE #PrimaryCare

Michael Albert MD, physician and co-founder at Accomplish Health, makes a call for responsible practices in obesity medicine. Exploitative companies entering the obesity treatment market are ‘…driven by commerce rather than a genuine commitment to patient health…’ with ‘…quick fixes and one-size-fits-all solutions.’ Albert rightly calls to distinguish ‘…between the commoditization of weight loss and the provision of comprehensive obesity care…’ from a transaction to a holistic and multi-faceted approach. Obesity is a serious and often lifelong chronic disease, necessitating multimodal and multidisciplinary care; I am all for convenience and technology, that must be delivered in a clinical-first, regulated and supportive manner. https://lnkd.in/egPV89rZ

During the last couple of days Embla's unique research has been displayed at the European Congress on Obesity (ECO) 2024 in Venice, and described on a number of global media platforms. The Mirror: https://lnkd.in/dhVE3C_S The Standard: https://lnkd.in/dxtyB7ua Perspective Media: https://lnkd.in/d3BAJAqV Our results show that patients can achieve approximately 15% weight loss when our digital service is combined with the use of semaglutide. The weight loss was achieved using only around one third of the usually applied semaglutide dose and that this is achievable regardless of patients initial BMI and the amount of semaglutide used. Moreover, our results show that continuous support through our digital platform (including support from mentors, nurses and physicians) enables tapering of semaglutide while maintaining the achieved weight loss. Henrik Rindel Gudbergsen Kine Stamp-Larsen Jesper Søndergaard Pedersen European Association for the Study of Obesity (EASO)

⭐The EASO Obesity Taxonomy Words matter and accurate framing and consistent terminology use is vital for ensuring: ✅ accurate diagnosis ✅ effective treatment ✅ consistent research ✅ clear communication ✅ informed policy-making ✅ overall improved patient outcomes. The EASO taxonomy provides a common language and a standardised and consistent framework for defining and classifying obesity. Read more about the six themes👇

Yesterday, I attended Digital Health New York's Obesity + Health conference with Victoria D.. The conference was a half day of goodness, but there were two sessions that stood out to me. The first was a panel discussion titled Patient Point of View: It’s About More Than Weight Loss where 3 people with obesity discussed their experiences ranging from medications to bariatric surgery to a supervised ketogenic diet supported by an app (Virta Health), care team, and community. Listening to people's struggles and hope reminded me why I decided to devote a significant part of my career to obesity. It also illustrated well how different people have different preferences, values, and responses to different interventions. One panelist used only a nutritional intervention with exercise, another was using a GLP-1 medication, and the third had undergone bariatric surgery years earlier and was also using multiple drugs to maintain her weight. The second was when panelist Katherine Saunders, MD spoke about her perspectives on obesity medication that closely mirror my own. Why are we so focused on maximizing doses of monotherapy with medications that have many side effects that are more common and prominent at higher doses? It is common knowledge that many medications produce much of their benefits at lower dosages, while side effects are dose dependent. Thus, previous research has shown better tolerability with good efficacy for multiple drugs at lower doses for other conditions like high blood pressure and lipid disorders. It's high time we start thinking about multi-drug regimens earlier rather than always maximizing doses of monotherapy AOMs. Hats off to Bunny Ellerin for a great conference! #obesity #pharmacotherapy #antiobesitydrugs #obesitymedicine #keto #glp1s

How can you cut through the weight-loss medication noise to deliver better health for your people without compromising fiscal responsibility? MedCity News featured an article by our Chief Medical Officer, Dr. Tim Church, MD, MPH, PhD, on his top five recommendations to deliver an effective obesity care plan – including using the entire spectrum of weight-loss medications for higher quality, more personalized care. Read now to learn how to better navigate this ever-evolving landscape, drastically decrease the rate of chronic conditions for your population, and increase the longevity and quality of life for your people: https://lnkd.in/gyvaPPpG

In the realm of precision medicine, which typically concentrates on highly specialized downstream targets, we at Resalis differentiate ourselves with a unique approach. Obesity is a complex and multifaceted disease that has consistently defied downstream treatments. That's where miR-22 comes in as an upstream target. By affecting a range of pathways involved in obesity, miR-22 offers a broader yet distinct approach to tackling this complex condition. Targeting miR-22 is analogous to addressing the root cause rather than just the symptoms, as our strategy aims to impact the plethora of underlying pathways of obesity to offer a more comprehensive treatment option. Resalis is at the forefront of this innovative approach, underscoring the significance of thoroughly understanding biological networks in obesity management.

The prevalence of #osteoarthritis in people with #obesity and the role of total diet replacement in clinical management. Professor Henning Bliddal, Director of the Parker Institute (a clinical research unit of #rheumatology at Frederiksberg University Hospital, Copenhagen) has recently spoken in a webinar hosted by TDMR Europe. Presenting existing research on the link between #obesity and #osteoarthritis, Prof Bliddal showed that an increase of one BMI point increases the risk of developing #kneeosteoarthritis by 15%. “It seems that having a BMI above 30 will give you almost double risk of acquiring hand osteoarthritis” he added. According to Prof Bliddal, 1kg #weightloss decreases osteoarthritis symptoms by almost 3% and a weight loss of 5% can reduce knee replacements by 25%. Prof Bliddal demonstrated that TDR can help people with obesity and knee osteoarthritis #loseweight and improve their health. 🔗 Click on the link in the comment to find out more